Amphenol enters its July 29 Q2 earnings report with a striking disconnect: the Street has been busy raising targets while the stock has quietly slid 5% on the week to $151.20.
The analyst story is the week's clearest signal. The direction of travel is uniformly upward — five firms lifted price targets in the past ten days, with no cuts among them. Citigroup moved its target to $195 from $180, reiterating Buy. Barclays nudged to $200, and Bank of America raised to $185, both keeping positive ratings. The consensus target now sits at $189.39, implying roughly 25% upside to the current price. That gap has widened precisely because the stock has drifted lower even as the Street grows more constructive — a setup worth noting ahead of the print.
The bull case rests on Amphenol's positioning across AI infrastructure, EV adoption, and defense. Bears flag slower industrial production, automotive supply chain friction, and the difficulty of finding attractive acquisition targets at reasonable multiples. Valuation is not cheap: the PE multiple is running near 28x on a trailing basis, down about 2.5 points over the past month as the stock corrected, and EV/EBITDA has eased to 16.4x. The short score sits at a relaxed 29 — ranking in the 81st percentile for low short pressure — which suggests the market's caution is expressed through reduced enthusiasm rather than active bearish conviction.
Positioning in the lending market reinforces that read. Short interest is low and falling — around 1.3% of free float, down 10% on the week and 8% over the past month. Borrow availability is essentially unlimited, with no friction whatsoever for anyone wanting to put on a short. Cost to borrow is just 0.42%, unremarkable despite a headline percentage change that reflects a brief anomalous dip on July 9 distorting the week-on-week comparison. Options positioning is mildly more cautious than usual: the put/call ratio is running at 0.88, slightly above its 20-day average of 0.85, but the z-score of 0.60 puts this well within normal range. None of this reads as a market bracing for bad news — it looks more like routine repositioning ahead of a scheduled event.
Institutional ownership is deep and stable. BlackRock holds just over 8% of shares, with FMR and Capital Research each above 5%. Capital Research added a notable 24 million shares in the period to June 30 — the largest single reported change among the top holders. On the insider side, the picture is one-directional: CEO Richard Norwitt sold roughly $18.7 million in stock in early May, following much larger sales of nearly $90 million in February. CFO Craig Lampo sold $15 million in February as well. These were routine plan-driven sales at prices between $142 and $150 — near where the stock trades today — but the volume is worth flagging as context. The one buy in the recent window was a $1.3 million open-market purchase by independent director Robert Livingston in early February at $128.51, a more constructive signal that has since moved into the money.
The last earnings print, on April 29, saw the stock gain 2.5% on the day before giving back those gains and more over the following week, finishing five days later down 3.7%. With the Street uniformly raising targets into the July 29 report and the stock already trading at a discount to consensus, the key question becomes whether the print itself — and management's commentary on AI-related revenue trajectory and industrial demand — is enough to close that gap or whether the same fade-after-beat pattern reasserts itself.
See the live data behind this article on ORTEX.
Open APH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
